Industry landscapes
The companies, capital and talent shaping life sciences in Boston. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
56 of 581 tracked companies have open roles.
345 of 581 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 773 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 14.0% of disclosed capital, while 40.6% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $957.96M | 39 | 53 |
| 2017 | $1.8B | 29 | 56 |
| 2018 | $1.44B | 32 | 55 |
| 2019 | $1.17B | 35 | 58 |
| 2020 | $1.73B | 46 | 57 |
| 2021 | $4.09B | 53 | 81 |
| 2022 | $1.99B | 33 | 62 |
| 2023 | $1.96B | 13 | 63 |
| 2024 | $2.69B | 13 | 67 |
| 2025 | $1.4B | 6 | 54 |
Share of all disclosed company funding.
854 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by .
Backed by .
Backed by .
Backed by StepStone Group and Benchmark and others.
Backed by Jetstream Venture Fund.
Backed by Janus Henderson Investors and RA Capital Management and others.
Backed by .
Backed by Merantix Capital and Seedcamp and others.
Backed by Gates.
Participating investors were not recorded in this snapshot.
Backed by T. Rowe Price and Cascade Investment Group and others.
Backed by Viking Global Investors and Y Combinator and others.
Backed by Ascenta Capital and New Enterprise Associates and others.
Backed by Ropes & Gray and ArrowMark Partners and others.
Backed by General Atlantic and Vida Ventures and others.
Backed by Sequoia Capital and Temasek and others.
Backed by Versant Ventures and Leaps by Bayer.
Backed by General Atlantic and Foresite Capital and others.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · annual statements grouped by reported fiscal year; exact entity periods remain on preview rows · 12 reporting entities from 28 eligible matches.
Sum of reporting-entity revenue; not Boston market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
1 of 12 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 12 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| Beta Bionics ↗1674632 | $100.3m | $-73.2m | -73.0% | — | — |
| WAVE Life Sciences ↗1631574 | $42.7m | $-204.4m | -478.3% | — | — |
| Myomo ↗1369290 | $40.9m | $-15.6m | -38.1% | — | — |
| InspireMD ↗1433607 | $9.0m | $-48.8m | -543.3% | — | — |
| Ziopharm Oncology ↗1107421 | $0.0m | $-4.2m | -83520.0% | — | — |
| 908 Devices ↗1555279 | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar |
| Entrada Therapeutics ↗1689375 | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar |
| Centessa Pharmaceuticals ↗1847903 | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar | Financial figure available in Radar |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the Boston companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
12 of these companies (2.1%) publish at least one Android app — 38 apps in all, carrying 237.3K installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Face2GeneFace2Gene | 176.1K | 1.7 | Medical |
| iLet AppBeta Bionics | 20.2K | 4.2 | Medical |
| Form HealthForm Health | 17.7K | 2.4 | Medical |
| Bionic CircleBeta Bionics | 9.4K | 4.1 | Medical |
| Purple CarrotPurple Carrot | 6.5K | 1.3 | Food & Drink |
| ParagonixParagonix Technologies | 3.2K | — | Medical |
| MX908 Remote (3.3+)908 Devices | 994 | — | Tools |
| Team Leader908 Devices | 763 | — | Business |
| FeelspaceCoStim Pharmaceuticals | 649 | — | Productivity |
| Food as MedicinePersonal Remedies | 503 | — | Medical |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q1–2025Q4).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Life Sciences Platforms And Tools | 4 | 178.2K | Face2Gene 176.1K | |
| Life Sciences Tech | 2 | 176.1K | ProCTH Patient 27 | |
| Diabetes | 2 | 29.6K | iLet App 20.2K | |
| Nutraceuticals Tech | 25 | 25.3K | Form Health 17.7K | |
| Disease Self Management | 26 | 18.9K | Food as Medicine 503 | |
| Fitness & Wellness Tech | 24 | 18.8K | Interstitial Cystitis (IC) 154 | |
| Assistive Tech | 3 | 214 | Myomo 120 | |
| Orthopedics | 2 | 144 | GateKeeper by Gate Science 24 |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 37 of 38 apps carry a release date. The series ends at 2025Q4, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
48 companies hiring · $22.29B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Size: 11.8 million shares at $16.00 to $18.00 to raise $200.6 million – if priced at the $17.00 mid-point of its range Market Cap: $861.36 million Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup and Stifel are the joint book-runners.
Boston-based AcuityMD a medtech intelligence platform that leverages AI and precise data to support commercial decision-making.
Eli Lilly has entered a definitive agreement to acquire Kelonia Therapeutics for up to $7 billion.
Deerfield Management Company L.P. boosted its holdings in shares of Praxis Precision Medicines by 22.4% in the 3rd quarter.
Life Biosciences (Boston), a biotech focused on therapies to reverse cellular aging, announced an $80 million Series D round to fund a cellular rejuvenation platform.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an agreement with an institutional healthcare investor for financing of up to $20 million.
Eli Lilly and Co. has agreed to acquire Centessa Pharmaceuticals for $38.00 per share in cash plus a contingent value right (CVR) worth up to $9.00 per share, implying a total potential equity value of approximately $7.8 billion.
Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE ) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $30 million to the Company before deducting placement agent fees and other private placement expenses (the “Offering”).
Private investment major Blackstone Inc is spearheading a $1.3bn private funding package to support the merger of Paratek Pharmaceuticals and Radius Health, according to a report by Bloomberg.
Cancer drug developer Aktis Oncology went public in New York last month,
Top 10 categories among 673 recorded events in the 24-month window.
19 companies with recorded IPO activity
IPO · Nasdaq2 reports
IPO · NASDAQ16 reports
IPO · Nasdaq10 reports
Follow-on Offering · Nasdaq1 reports
SPAC · Nasdaq2 reports
Follow-on Offering · Nasdaq1 reports
Follow-on Offering5 reports
IPO · Nasdaq2 reports
46 tracked people moves
Appointment Chief Causal AI Officer
Appointment Board of Directors
Resignation
Appointment Chief People Officer
Appointment EVP, chief commercial officer (CCO)
Appointment chief corporate affairs officer
Promotion Chief Operating Officer (COO)
Appointment Country Director
Products, platforms and features in the recorded window
Digital Pathology Platform
AI platform
1 recorded customer wins
Customer: genentechPharma
9 companies with reported reductions
Scale not stated rolesregulatory framework
50.0% rolescost reduction
50 rolesstreamline pipeline
63 rolescost reduction
338 rolesacquisition by Supernus
20.0% rolesresource focus
9 recorded events
CE approvalEuropean Commission
license granted
approved for post‑partum depressionFDA
rejected for major depressive disorderFDA
18 tracked suits
securities fraudClass Action · Ongoing
securities fraud / shareholder rights violationClass Action · Ongoing
Reported company results in the recorded window.
Median across 84 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| eli lilly→Kelonia ↗ | Completed | 2026-04-28 | $7.0B |
| lilly→Kelonia ↗ | Announced | 2026-04-20 | $7.0B |
| allspring global investments→Praxis Medicines ↗ | Announced | 2026-04-12 | $496.0K |
| Woodline Partners LP→Praxis Medicines ↗ | Announced | 2026-04-12 | $22.1M |
| Adage Capital Partners GP L.L.C.→Praxis Medicines ↗ | Announced | 2026-04-12 | $83.0M |
| Deerfield Management Company L.P.→Praxis Medicines ↗ | Announced | 2026-04-12 | $44.6M |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
827 postings in the preceding 12 months. The full 1,183-posting snapshot covers 65 employers.
9 tracked postings mention remote work.
728 postings specify a level.
Top skills across 1,183 tracked postings in the available jobs snapshot.
Median across 166 postings with pay data, expressed in USD.
Advertised posting medians do not describe all employees or roles.
| Company | Open roles |
|---|---|
| Insulet ↗ | 12 |
| TetraScience ↗ | 10 |
| Paragonix Technologies ↗ | 9 |
| SCIEX ↗ | 9 |
| InspireMD ↗ | 7 |
| Elektrofi ↗ | 7 |
| OneStudyTeam ↗ | 6 |
| Radius Health ↗ | 6 |
| Company | Employees |
|---|---|
| Insulet ↗ | 2,600 |
| Ginkgo Bioworks ↗ | 1,218 |
| Concert AI ↗ | 1,000 |
| BICO ↗ | 955 |
| Velsera ↗ | 834 |
| PathAI ↗ | 573 |
| OneStudyTeam ↗ | 309 |
| WAVE Life Sciences ↗ | 233 |
490 founders and chief executives across 318 companies.
Ginkgo Bioworks, ex-Massachusetts Institute Of Technology, Massachusetts Institute of Technology, 2008
Care Access, ex-Signal Vine, ex-Rock Health, The Johns Hopkins University School of Medicine
Dewpoint Therapeutics, ex-Sanofi, ex-Novartis, Middlesex Hospital Medical School, 1991
Ex-Mass Innovation Labs, Advanced Peptides
Ex-Karuna Therapeutics. Tulane University, Tulane University School of Medicine MS
Partner - Flagship Pioneering. Harvard T.H. Chan School of Public Health Master of Public Health 2008
Universite De Marseille 1981
ARTIS Ventures, vTv Therapeutics, ex-CEO Pfizer, McDonald's, GE, Williams & Connolly. Tufts University 1977, Harvard University JD 1980
CEO KSQ Therapeutics.
Ex-VP Pequot Ventures, McKinsey & Company. The Johns Hopkins University BA 2001, Massachusetts Institute of Technology PhD 2001
Ex-Beth Israel Deaconess Medical Center. Brown Medical School MD 2006, Stanford University PhD 2013
Ex-Cerevel Therapeutics, scPharmaceuticals, Keryx Biopharmaceuticals, Ironwood Pharmaceuticals…
163 profiles with education records.
14 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
7,288 articles in the measured 12-month window.
Life Sciences coverage tagged Boston · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 2,102 |
| 2021Q3 | 2,130 |
| 2021Q4 | 1,795 |
| 2022Q1 | 2,213 |
| 2022Q2 | 2,095 |
| 2022Q3 | 2,065 |
| 2022Q4 | 2,258 |
| 2023Q1 | 2,180 |
| 2023Q2 | 2,898 |
| 2023Q3 | 2,058 |
| 2023Q4 | 2,654 |
| 2024Q1 | 2,658 |
| 2024Q2 | 2,734 |
| 2024Q3 | 2,124 |
| 2024Q4 | 2,052 |
| 2025Q1 | 6,612 |
| 2025Q2 | 1,598 |
| 2025Q3 | 1,544 |
| 2025Q4 | 2,458 |
| 2026Q1 | 1,792 |
Article volume measures coverage, not market sales.
1,020 recorded company events across 112 companies; percentages use that event total.
Life Sciences coverage tagged Boston · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
United States comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| vaccine candidates | 3,157 | 898 | 252% |
| vaccine trials | 2,962 | 904 | 228% |
| vaccination campaigns | 2,752 | 555 | 396% |
| vaccine immunogenicity | 2,473 | 668 | 270% |
| mass vaccination sites | 2,021 | 272 | 643% |
| vaccination coverage | 1,516 | 202 | 650% |
| vaccine effectiveness study | 1,400 | 251 | 458% |
| angel investors | 1,344 | 590 | 128% |
| covid-19 vaccine development | 1,335 | 238 | 461% |
| pandemic vaccine stockpiling | 1,294 | 242 | 435% |
| investigational new vaccine | 451 | 1,069 | -58% |
| cell-based therapies | 619 | 1,059 | -42% |
| viral vector vaccines | 684 | 1,048 | -35% |
| cancer biomarkers | 670 | 1,040 | -36% |
| diagnostic biotechnology | 570 | 948 | -40% |
United States comparison coverage
core inflation rate, inflation outlook, inflation breakdown
52.8% critical · 34.6% positiveangel investors, vaccine candidates, vaccine trials
49.1% critical · 55.2% positivegdp acceleration, gdp growth rate, economic output growth
49.7% critical · 39.6% positiveLife Sciences coverage tagged Boston. Topic labels describe recorded classifications and can include broad context.
6,260 papers in the recorded india scope.
Tone counts: 5,526 positive · 456 neutral · 278 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: U1 snRNP regulates cancer cell migration and invasion in vitro
Common problems researchers identify · 0118.4% of this theme group
Researchers highlight technical hurdles in synthetic biology, enzymatic processes, and nanotech for biotech production.
Biochemical engineering (18) · Synthetic biology (12) · Biomanufacturing (8) · Nanotechnology (9)
Microbial Enzymes: Tools for Biotechnological Processes
Medical biofilms
| Year | Share index |
|---|---|
| 2022 | 67.9 |
| 2023 | 70.3 |
| 2024 | 84.4 |
| 2025 | 67.1 |
Common problems researchers identify · 0215.7% of this theme group
Studies flag rising contamination threats and public‑health impacts from unsafe food and produce.
Public health (15) · Mycotoxin (8) · Disease (12) · Contamination (8)
The growing burden of foodborne outbreaks due to contaminated fresh produce: risks and opportunities
A review of Listeria monocytogenes: An update on outbreaks, virulence, dose-response, ecology, and risk assessments
| Year | Share index |
|---|---|
| 2022 | 301.0 |
| 2023 | 265.8 |
| 2024 | 276.2 |
| 2025 | 304.0 |
Common problems researchers identify · 0315.5% of this theme group
Papers discuss mutation detection, DNA methylation complexities, and metabolic profiling in oncology.
Mutation (7) · Cancer (9) · DNA methylation (5) · Gene (8)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine
| Year | Share index |
|---|---|
| 2022 | 974.1 |
| 2023 | 1199.2 |
| 2024 | 866.8 |
| 2025 | 797.1 |
Common problems researchers identify · 0415.2% of this theme group
Works point to difficulties in engineering crops for drought, salinity, and other non‑biotic stresses.
Agriculture (33) · Abiotic stress (10) · Abiotic component (12) · Biotechnology (20)
Genetic Engineering for Modern Agriculture: Challenges and Perspectives
Phytohormones and their metabolic engineering for abiotic stress tolerance in crop plants
| Year | Share index |
|---|---|
| 2022 | 1472.5 |
| 2023 | 1503.8 |
| 2024 | 1656.9 |
| 2025 | 1839.0 |
Common problems researchers identify · 0514.7% of this theme group
Research notes obstacles in biofortification, micronutrient production, and beneficial food fermentations.
Micronutrient (9) · Production (13) · Nutrient (10) · Food science (7)
Improving nutrition through biofortification: A review of evidence from HarvestPlus, 2003 through 2016
Food fermentations: Microorganisms with technological beneficial use
| Year | Share index |
|---|---|
| 2022 | 120.6 |
| 2023 | 117.1 |
| 2024 | 113.1 |
| 2025 | 122.2 |
Common problems researchers identify · 0611.1% of this theme group
Authors emphasize the growing threat of resistant bacteria and the need for new antimicrobial strategies.
Antibiotic resistance (49) · Antimicrobial (31) · Antibiotics (22) · Drug resistance (8)
An overview of the antimicrobial resistance mechanisms of bacteria
The global threat of antimicrobial resistance: science for intervention
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Common problems researchers identify · 079.5% of this theme group
Studies outline resistance mechanisms in pests and challenges for integrated control programs.
Resistance (14) · Insecticide resistance (5) · Vector (5) · Integrated pest management (5)
Insecticide Resistance in Mosquitoes: Impact, Mechanisms, and Research Directions
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
| Year | Share index |
|---|---|
| 2022 | 3.4 |
| 2023 | 3.1 |
| 2024 | 4.4 |
| 2025 | 4.3 |
Cautions · 0124.6% of this theme group
Researchers urge caution interpreting genomic instability and mutation data due to repair pathway complexities.
DNA repair (7) · DNA polymerase (6) · DNA damage (7) · Mutation (9)
Examining the link between chromosomal instability and aneuploidy in human cells
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
| Year | Share index |
|---|---|
| 2022 | 101.2 |
| 2023 | 139.0 |
| 2024 | 91.9 |
| 2025 | 79.2 |
Cautions · 0218.1% of this theme group
Papers caution about unintended immune effects when targeting antibodies or cellular subsets in vivo.
Antibody (9) · In vivo (8) · Peripheral blood mononuclear cell (4) · Immune system (5)
Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs
T cell responses towards PINK1 and ⍺-synuclein are elevated in prodromal Parkinson's disease - Fluorospot data
| Year | Share index |
|---|---|
| 2022 | 543.7 |
| 2023 | 602.0 |
| 2024 | 448.8 |
| 2025 | 441.1 |
Cautions · 0314.4% of this theme group
Works warn of potential health and quality issues from nanomaterials in raw food ingredients.
Food safety (6) · Raw material (4) · Health benefits (4) · Sugar (3)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Soybean susceptibility to manufactured nanomaterials with evidence for food quality and soil fertility interruption
| Year | Share index |
|---|---|
| 2022 | 122.8 |
| 2023 | 120.4 |
| 2024 | 118.6 |
| 2025 | 154.1 |
Cautions · 0411.6% of this theme group
Studies highlight uncertainties in additive use, animal performance, and greenhouse‑gas outcomes.
Dairy cattle (6) · Production (6) · Nutrient (6) · Beef cattle (5)
Impact of tannin-based additives on animal performance and enteric methane emissions in dairy and beef cattle: A meta-analysis
The effects of injectable trace mineral solutions on beef cattle performance and health during preconditioning and feedlot receiving: a syst
| Year | Share index |
|---|---|
| 2022 | 126.8 |
| 2023 | 122.4 |
| 2024 | 118.5 |
| 2025 | 129.2 |
Cautions · 0510.8% of this theme group
Researchers note challenges in predicting traits and maintaining diversity using genomic breeding tools.
Gene (10) · Genomic selection (5) · Selection (6) · Trait (4)
Genomic Selection for Crop Improvement
Genomic selection in plant breeding: from theory to practice
| Year | Share index |
|---|---|
| 2022 | 2367.9 |
| 2023 | 2351.5 |
| 2024 | 2081.1 |
| 2025 | 1566.0 |
Cautions · 0610.5% of this theme group
Papers point to practical and ecological concerns when deploying biological control and pesticide strategies.
PEST analysis (9) · Agriculture (7) · Pest control (3) · Integrated pest management (3)
The use of fungal entomopathogens as endophytes in biological control: a review
Insecticide Control of Vector-Borne Diseases: When Is Insecticide Resistance a Problem?
| Year | Share index |
|---|---|
| 2022 | 1443.5 |
| 2023 | 1484.3 |
| 2024 | 1642.9 |
| 2025 | 1827.1 |
Cautions · 079.9% of this theme group
Works caution that veterinary antibiotic practices can influence resistance patterns in human pathogens.
Antibiotic resistance (12) · Antibiotics (9) · Antimicrobial (6) · Bacteria (5)
Multidrug evolutionary strategies to reverse antibiotic resistance
Impact of Antibiotic Use in Adult Dairy Cows on Antimicrobial Resistance of Veterinary and Human Pathogens: A Comprehensive Review
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Opportunities · 0119.6% of this theme group
Research explores microbial products for improving human health, animal performance, and food safety.
Antimicrobial (64) · Fermentation (55) · Bacteria (52) · Antibiotic resistance (37)
Probiotics, their health benefits and applications for developing healthier foods: a review
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 2406.7 |
| 2023 | 2240.7 |
| 2024 | 2316.1 |
| 2025 | 1955.8 |
Opportunities · 0219.3% of this theme group
Studies identify novel gene‑knockdown and pathway modulation approaches for disease therapy.
Apoptosis (37) · Downregulation and upregulation (57) · Gene knockdown (46) · Mutant (48)
PCBP1 binding to single-stranded poly-cytosine motifs enhances cGAS sensing and impairs breast cancer development
Modulation of ossification and inflammatory pathways during dexamethasone-induced <i>in vitro</i> osteogenesis
| Year | Share index |
|---|---|
| 2022 | 364.0 |
| 2023 | 394.7 |
| 2024 | 257.4 |
| 2025 | 261.8 |
Opportunities · 0313.2% of this theme group
Papers present new antibody targets and microvesicle strategies to enhance T‑cell mediated treatments.
Cell culture (77) · T cell (54) · Antigen (49) · Cell (62)
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes
| Year | Share index |
|---|---|
| 2022 | 289.3 |
| 2023 | 336.1 |
| 2024 | 224.8 |
| 2025 | 204.1 |
Opportunities · 0412.8% of this theme group
Research highlights emerging methods to correct methylation defects and manipulate replication processes.
DNA repair (65) · DNA damage (68) · DNA methylation (58) · DNA replication (34)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
MacroH2A-Mediated Gene Repression through Nucleosome Compaction and Remodeling Inhibition
| Year | Share index |
|---|---|
| 2022 | 224.2 |
| 2023 | 281.6 |
| 2024 | 196.5 |
| 2025 | 158.4 |
Opportunities · 0512.2% of this theme group
Works develop activatable nanoprobes for real‑time fluorescence and magnetic resonance tracking in vivo.
In vivo (142) · Fluorescence (41) · Molecular imaging (28) · Nanotechnology (33)
Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases
Recognition, Neutralization, and Clearance of Target Peptides in the Bloodstream of Living Mice by Molecularly Imprinted Polymer Nanoparticl
| Year | Share index |
|---|---|
| 2022 | 480.4 |
| 2023 | 520.5 |
| 2024 | 397.5 |
| 2025 | 406.8 |
Opportunities · 0611.7% of this theme group
Studies showcase sequencing and selection techniques to broaden germplasm and accelerate crop improvement.
Germplasm (37) · Selection (42) · Genetic diversity (28) · Trait (28)
Genotyping‐by‐Sequencing for Plant Breeding and Genetics
Harvesting the Promising Fruits of Genomics: Applying Genome Sequencing Technologies to Crop Breeding
| Year | Share index |
|---|---|
| 2022 | 56.0 |
| 2023 | 51.4 |
| 2024 | 46.1 |
| 2025 | 53.1 |
Opportunities · 0711.3% of this theme group
Research investigates mRNA methylation and microRNA pathways for controlling gene expression in disease.
Messenger RNA (103) · microRNA (61) · Transcription (65) · RNA polymerase II (34)
m <sup>6</sup> A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation
Microrna-Dependent Regulation of Dna Methyltransferase-1 and Tumor Suppressor Gene Expression by Interleukin-6 in Human Malignant Cholangioc
| Year | Share index |
|---|---|
| 2022 | 229.2 |
| 2023 | 195.8 |
| 2024 | 157.3 |
| 2025 | 136.5 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Breakthrough | 32.6% | 26.7% |
| Promising | 31.0% | 37.0% |
| Descriptive | 17.5% | 17.4% |
| Problem-identifying | 9.1% | 9.6% |
| Cautionary | 5.8% | 4.4% |
| Comparative | 2.8% | 4.0% |
| Critical | 1.3% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 18 | 0.3% | 2 (11.1%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 4 | 0.07% | 1 (25.0%) | 0.15% |
| Bias & fairnessNot All Allies Are Welcome: Partner Discrimination in Legume–Rhizobium Symbiosis | 3 | 0.05% | 1 (33.3%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 1 | 0.02% | 1 (100.0%) | 0.01% |
| Energy & datacenter footprint | 0 | 0.0% | 0 (%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: United States. This may be broader than the company geography.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 2 September 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗